By Karen Roman Biotechnology company Medera Inc. said it will start the Cohort B (high-dose) trial of SRD-002, the first-in-human cardiac gene therapy for Heart Failure with Preserved Ejection Fraction. The company finished Cohort A (low-dose) with favorable efficacy results after...

By Daniella Parra March Biosciences has closed an oversubscribed $28.4 million Series A financing, led by Mission BioCapital and 4BIO Capital to advance its innovative autologous chimeric antigen receptor T-cell (CAR-T) therapy and more, it said. The therapy is aimed...

By Karen Roman MOBILion Systems, Inc. revealed its hi-res mass spectrometry functionality with implementations for proteomics, metabolomics and lipidomics, among others. The company’s approach is up to 5-10 times faster than current systems, close to 100% ion utilization efficiency and it...

By Karen Roman Global surgical robotics company CMR Surgical said the FDA has granted marketing authorization for its Versius Surgical Robotic System in the U.S.   Versius is the world’s second most utilized surgical robotic system with over 26,000 procedures...

Jack Truong, known for spearheading a series of high-profit corporate makeovers, reveals why taking an uncomfortable path often leads to success. By Exec Edge Editorial Staff As defined by Investopedia, disruptive innovation “transforms expensive or highly sophisticated products or services...

By Karen Roman Diagnostics company SkylineDx said it will present clinical data on the success of its Merlin test at the 21st International Congress of the Society for Melanoma Research 2024 in New Orleans. The CP-GEP Merlin test accurately stratifies...

Tech Edge hosted a fireside chat with Qualys, Inc. (Nasdaq: QLYS) to discuss the company’s 25th year anniversary, the launch of the Enterprise TruRisk Management platform, and more. The event featured Qualys’ President and CEO Sumedh Thakar, moderated by Exec...

By Daniella Parra Recordati said it will acquire the global rights to Enjaymo, used to treat a rare blood disorder, from Sanofi. Enjaymo has been approved by the FDA, European Commission, and Japan’s Ministry of Health, the company said. Recordati...

By Karen Roman Winemaker The Duckhorn Portfolio, Inc. (NYSE: NAPA) said it will be taken private in an all-cash deal worth $1.95 billion by Butterfly Equity, in a transaction expected to conclude this winter. The private equity firm agreed to...

By Karen Roman Eliem Therapeutics, Inc. (Nasdaq: ELYM) said its new corporate name will be Climb Bio, Inc. and it will start trading at Nasdaq with the ticker symbol “CLYM” on Oct. 3. This rebranding reflects Climb’s laser-focused mission on...